Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis

BackgroundThe EGFR gene encodes a protein that stimulates molecular pathways that allow the growth and development of the tumor microenvironment. The current preferred tyrosine kinase inhibitor (TKI) for the first-line treatment of EGFRm metastatic non-small cell lung cancer (NSCLC) is osimertinib....

Cijeli opis

Bibliografski detalji

Glavni autori:	Rodrigo Motta-Guerrero, Alejandro Leon Garrido-Lecca, Virgilio E. Failoc-Rojas, Ana Calle-Villavicencio, Robert Villacorta-Carranza, Yesenia Huerta-Collado, Alicia Torres-Mera, Mario J. Valladares-Garrido, Víctor Rivera-Francia, Carlos Carracedo, Luis Raez
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-01-01
Serija:	Frontiers in Oncology
Teme:	non-small cell lung cancer EGFR gene VEGFR tyrosine kinase inhibitor erlotinib
Online pristup:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1335373/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!